| EPB0153 | Drug Resistant Tuberculosis (DR-TB) detection among new, previously treated TB cases, and people living with HIV in Western and Southern highlands, Tanzania | E-poster | Co-infections (including opportunistic infections) |
| EPB0154 | Finding missing tuberculosis (TB) cases in Ugandan military health facilities through use of mobile digital X-ray services and technology (Mobile TB Clinics) | E-poster | Co-infections (including opportunistic infections) |
| EPB0155 | Readiness for HCV care provision for men who have sex with men in seven countries | E-poster | Co-infections (including opportunistic infections) |
| EPB0156 | Decrease of Yellow Fever neutralizing antibody titers one year after vaccination is related to different NK cells repertoire in PLWH and non-HIV controls - ANRS12403 | E-poster | Co-infections (including opportunistic infections) |
| EPB0157 | Health system strengthening approach improves national TB preventive therapy (TPT) coverage in Malawi | E-poster | Co-infections (including opportunistic infections) |
| EPB0158 | Incidence of occult hepatitis B virus among people living with HIV in Botswana | E-poster | Co-infections (including opportunistic infections) |
| LBEPB13 | Week-96 results of ALLIANCE, a phase 3, randomized, double-blind study comparing bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus dolutegravir + emtricitabine/tenofovir disoproxil fumarate (DTG+F/TDF) in treatment-naïve people with both HIV-1 and hepatitis B | E-poster | Co-infections (including opportunistic infections) |
| LBPEB03 | Combined “Test and Treat” campaigns for HIV, hepatitis B and hepatitis C: a systematic review to provide evidence to support WHO treatment guidelines | Poster exhibition | Co-infections (including opportunistic infections) |
| MOPEB02 | Missed opportunities with symptom-based testing of chlamydia and gonorrhea among men who have sex with men and transgender women attending key population-led clinics in Thailand | Poster exhibition | Co-infections (including opportunistic infections) |
| MOPEB03 | Safety and efficacy of 6-month rifampicin resistant TB regimens in people living with HIV: final analysis | Poster exhibition | Co-infections (including opportunistic infections) |